- Poster presentation
- Open Access
Development of a core outcome set based on Case Report Form (CRF) to assess laboratory biomarkers and clinical parameters in Onco-Hematology area
© Vanalli and Rio; licensee BioMed Central Ltd. 2015
Published: 29 May 2015
The number of cases, the crude and age-standardized incidence, mortality rates and the prevalence proportions estimated by the Italian Association of Cancer Registries (AIRTUM) presently providing the epidemiological indicators for the major cancers used in ICD-O-3.1 [1–3]. By 2012, the breast cancer incidence in women (age 25±over 85 years) was about 29%; trends for stomach and colorectal cancer were about 5% and 14% for both genders (age 35/45±over 85 years); the lung cancer incidence rates was about 15% in men (age 45±over 85 years) and 6% in women (age 40±over 85) in 2009 [4, 5]. From 2011 onwards the tendency changed: the female rates (20 per 100,000) increased much more rapidly than the male rates .
Aim of this study is to examine the relationships among the incidence of genera-cancer-associated risk factors and routine laboratory in cancer patients through CRF.
Materials and Methods
Multivariate Analyses of cancer type, comorbidity score and biomarkers laboratory
This study was conducted with three Italian Oncological Institutions funded by Cancer Research in Bergamo, Milan and Rome. The author would like to thank General Directors and Nurse Directors of these Hospitals for authorizing the study; patients, nursing coordinators, nurses working in Onco-Hematology area for their hospitality and support in data collection process and for their assistance in patient recruitment.
- Abbasi S, Badheeb A: Prognostic factors in advanced non-small-cell lung cancer patients: Patient characteristics and type of chemotherapy. Lung Cancer International. 2011, 0 (0): 1-4.View ArticleGoogle Scholar
- Albain KS, Crowley JJ, LeBlanc M, Livingston RB: Survival determinants in extensive-stage non-small-cell lung cancer: The Southwest Oncology Group experience. Journal of Clinical Oncology. 1991, 9: 1618-1626.PubMedGoogle Scholar
- American Cancer Society: Cancer facts and figures. 2012, Retrieved from [http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-031941.pdf]. Accessed November 21, 2014Google Scholar
- Boyd CM, Vollenweider D, Puhan MA: Informing evidence-based decision-making for patients with comorbidity: availability of necessary information in clinical trials for chronic diseases. PLoS ONE. 2012, 7: e41601-10.1371/journal.pone.0041601.View ArticlePubMedPubMed CentralGoogle Scholar
- Charlson ME, Pompei P, Ales KL, MacKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis. 1987, 40 (5): 373-383. 10.1016/0021-9681(87)90171-8.View ArticlePubMedGoogle Scholar
- Corbett J: Laboratory tests and diagnostic procedures with nursing diagnoses. 2008, Upper Saddle River, NJ: Pearson/Prentice Hall, 7Google Scholar
- Cox D, Oakes D: Analysis of survival data. 1984, London, England: Chapman and HallGoogle Scholar
- Foucher ES, O’Callaghan M, Ferlay J, Masuyer E, Rosso S, Forman D, Bray F, Comber H: The European Cancer Observatory: A new data resource. European Journal of Cancer. 2014, 0 (0): 1-13.Google Scholar
- Gatta G, Ciampichini R, Bisanti L, Contiero P, Tessandori R, Baili P, Rossi S: Estimates of cancer burden in Lombardy. Tumori. 2013, 99 (3): 277-84.PubMedGoogle Scholar
- Grande E, Inghelmann R, Francisci S, Verdecchia A, Micheli A, Baili P, Capocaccia R, De Angelis R: Regional estimates of all cancer malignancies in Italy. Tumori. 2007, 93: 345-351.PubMedGoogle Scholar
- Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics. A Cancer Journal for Clinicians. 2009, 59 (4): 225-249. 10.3322/caac.20006.View ArticleGoogle Scholar
- International Agency for Research on Cancer: Cancer Incidence in Five Continents Annual Dataset. 2014, Accessed November 21, [http://ci5.iarc.fr/CI5plus/ci5plus.htm]Google Scholar
- Luo J, Chen YJ, Narsavage GL, Ducatman A: Predictors of Survival in Patients with Non-Small Cell Lung Cancer. Oncology Nursing Forum. 2012, 39 (6): 609-16. 10.1188/12.ONF.609-616.View ArticlePubMedGoogle Scholar
- Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, Mc-fadden ET, Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. American Journal of Clinical Oncology. 1982, 5 (6): 649-655. 10.1097/00000421-198212000-00014.View ArticlePubMedGoogle Scholar
- Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P, Januel JM, Sundararajan V: Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011, 173: 676-82. 10.1093/aje/kwq433.View ArticlePubMedGoogle Scholar
- Radovanovic D, Seifert B, Urban P, Eberli FR, Rickli H, Bertel O, Puhan MA, Erne P: Validity of Charlson Comorbidity Index in patients hospitalised with acute coronary syndrome. Insights from the nationwide AMIS Plus registry 2002-2012. Heart. 2014, 100 (4): 288-94. 10.1136/heartjnl-2013-304588. [ClinicalTrials.gov Identifier NCT01305785]View ArticlePubMedGoogle Scholar
- Yurkovich M, Zubieta JAA, Thomas J, Gorenchtein M, Lacaille D: A systematic review identifies valid comorbidity indices derived from administrative health data. Journal of Clinical Epidemiology. 2015, 68: 3-14. 10.1016/j.jclinepi.2014.09.010.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.